We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




MR-Guided Focused Ultrasound Relieves Pain from Bone Metastases

By HospiMedica International staff writers
Posted on 02 Dec 2008
Physicians are evaluating new ways to use magnetic resonance imaging (MRI) and ultrasound to relieve some of the extreme pain resulting from cancer that has metastasized to the bones. More...


"Bone metastases are one of the most common causes of pain for cancer patients," said Dr. King Li, chair of the department of radiology at the Methodist Hospital (Houston, TX, USA) and lead investigator for the trial. "Unfortunately, current treatments to relieve this intense pain are very limited."

Typical painkilling or palliative treatment includes invasive surgery that many late-stage cancer patients cannot tolerate, radiation that damages more tissue than necessary, or nerve ablation. In this study, MRI technology was used to visualize the patient's anatomy and then aims focused ultrasound waves at the targeted tissue, using low-level heat to ablate, or destroy it, reducing or eliminating the pain. This new method of using MR-guided focused ultrasound (MRgFUS) may provide a completely non-invasive way to relieve pain, according to Dr. Li.

In earlier clinical studies performed in Europe, most of the patients reported pain relief within days of treatment. "This is an important trial because 90% of patients with a progressive form of breast cancer have bone metastases, and almost all patients with metastatic prostate cancer have tumors that spread to the bones," Dr. Li said.

MRI scanning allows the clinician to monitor and continuously modify the treatment in real time. Due to inherent structural characteristics of the bone tissue, it is possible to use a low level of heat and achieve the desired effect, while minimizing damage to adjacent tissue.

The U.S. Food and Drug Administration (FDA) approved this technology, MRgFUS, to treat uterine fibroids in 2004. This same technology has shown promising effectiveness and safety results in pain-palliation feasibility studies in patients who have in-bone metastases, and researchers hope to validate those results though this larger investigational trial.

Related Links:

Methodist Hospital



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
X-Ray System
Leonardo DR mini III
Morcellator
TCM 3000 BL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.